Personalize My Medicine is please to announce a partnership with SMi´s 7th annual Orphan Drugs & Rare Disease conference!
7th annual Orphan Drugs and Rare Diseases UK
18th & 19th October 2017
Holiday Inn Kensington Forum, London, UK
Organisers: SMi Group
Tel: +44 (0) 207 827 6012
http://
www.orphandrugs.co.uk/PMMed

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
 
Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.
 
Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.
 
Featured Speakers:
  • Olivier Morand, Clinical Science Program Head, Actelion Pharmaceuticals
  • Larissa Kerecuk, Rare Disease Lead, Consultant Paediatric Nephrologist, Birmingham Children’s Hospital
  • Oliver Timmis, CEO, AKU Society
  • Stuart Hughes, Director, Head of Pharmacology, Vertex
  • Nadia Assenova, Senior Director Regulatory Affairs, EMEA, Alexion Pharma GmbH
  • Christine Lavery, Group Chief Executive, MPS Society
  • Hsin Loke, Director, Strategy, Operations and Finance, Rare Diseases Unit, GlaxoSmithKline
  • Olaf Ritzeler, External Innovation Lead, Sanofi
  • Stephen Marcus, CEO, Cantex Pharmaceuticals
  • Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Exclusive highlights in 2017:
  • Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
  • Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
  • Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more
  • Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug repurposing in the rare disease area can help treatment